GIC, Sovereign Fund of Singapore, acquired minority slice from the Brazilian pharmacist Cimed. The percentage of participation was not disclosed. The entrance of the fund to the company was advised by JP Morgan and Spinelli Advogados. With the entry of the new partner, the pharmacist presided by João Adibe Marques, the “João da Cimed”, continues an ambitious growth plan, which provides revenues of R $ 5 billion this year and R $ 10 billion by 2030.
“We are proud to have a strategic partner with global connection like GIC to accelerate our growth journey,” the CEO said in a press release.
Starting from the principle that the size of the portfolio must be increased to achieve its goals, Cimed is turbocharging its consumer division, which does not depend on the wait for patent fall and already accounts for more than 60% of the company’s revenue.
Continues after advertising
Adibe signaled 130 new products in 2025. More than 70 hit the market in the first quarter of this year. The news was announced in the month of the past in a summit MSA pharmacist (acronym for “my yellow blood”) in which Cimed invested $ 30 million.
To get the plan to fold the size in five years, Cimed predicts investing $ 2 billion during this period.
